GlassScriptPhysician profile
Kathryn Flavin
NPI 1083032064
$2,565.49
in general payments reported to CMS, 2019-2025
11 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,422 · 2020: $1,128 · 2022: $15.58.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vertos Medical, INC. | $1,079.24 | 2019-2020 | |
| Nevro Corp. | $725.27 | 2019 | |
| Vertiflex, INC. | $200.79 | 2019 | |
| Boston Scientific Corporation | $186.55 | 2019-2020 | |
| Radius Health, INC. | $166.20 | 2019-2020 | |
| Ucb, INC. | $90.40 | 2020 | |
| Indivior INC. | $42.19 | 2019-2020 | |
| Medtronic USA, INC. | $31.28 | 2019 | |
| Glaxosmithkline, LLC. | $15.58 | 2022 | |
| Allergan, INC. | $14.58 | 2020 | |
| Amgen INC. | $13.41 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kathryn Flavin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.